US2022185877A1PendingUtilityA1

Antibody heavy chain constant domains

80
Assignee: BRISTOL MYERS SQUIBB COPriority: May 22, 2012Filed: Jan 7, 2022Published: Jun 16, 2022
Est. expiryMay 22, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Brenda L. StevensMark W. RixonScott R. Presnell
A61P 11/06A61P 11/00A61P 17/06A61P 9/00C07K 2317/55A61P 13/12A61P 25/00C07K 2317/565C07K 2317/34A61K 2039/505C07K 2317/31A61P 1/00A61P 9/10A61P 19/02C07K 2317/92C07K 16/468A61P 1/02A61P 19/00C07K 2317/24C07K 16/244A61P 29/00C07K 2317/76A61P 37/06A61P 17/00C07K 2317/21A61P 37/00A61P 27/02A61P 37/02
80
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a constant domain comprising an amino acid sequence of SEQ ID NO:127. 
     
     
         2 . The isolated antibody of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         3 . The isolated antibody of  claim 1 , wherein the antibody is a bispecific antibody. 
     
     
         4 . The isolated antibody of  claim 1 , wherein the antibody is a human antibody. 
     
     
         5 . The isolated antibody of  claim 1 , wherein the antibody is a humanized antibody. 
     
     
         6 . A composition comprising the antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         7 . An isolated antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a constant domain comprising an amino acid sequence of SEQ ID NO:128. 
     
     
         8 . The isolated antibody of  claim 7 , wherein the antibody is a monoclonal antibody. 
     
     
         9 . The isolated antibody of  claim 7 , wherein the antibody is a bispecific antibody. 
     
     
         10 . The isolated antibody of  claim 7 , wherein the antibody is a human antibody. 
     
     
         11 . The isolated antibody of  claim 7 , wherein the antibody is a humanized antibody. 
     
     
         12 . A composition comprising the antibody of  claim 7  and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2022185877A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.